Evidence map›Paper›PMID 40776643›Full record

ArticleCurrent medicinal chemistry2026

Discovery of Furan-tethered Triazolothiadiazoles and Triazolothiadiazines as Potent Tyrosinase Inhibitors for the Treatment of Skin Diseases: Insights from Kinetics Data and Computational Modeling.

Majid Khan, Atta Ullah, Sobia Ahsan Halim, Imtiaz Khan, Sumera Zaib, Humaira Hussian, Magda H Abdellattif, Afnan Jan, Aliya Ibrar, Ajmal Khan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Majid KhanNatural and Medical Sciences Research Center, University of Nizwa, , Birkat Al Mauz, Nizwa, PO Box 33, 616, Oman.
Atta UllahNatural and Medical Sciences Research Center, University of Nizwa, , Birkat Al Mauz, Nizwa, PO Box 33, 616, Oman.
Sobia Ahsan HalimNatural and Medical Sciences Research Center, University of Nizwa, , Birkat Al Mauz, Nizwa, PO Box 33, 616, Oman.
Imtiaz KhanDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom.
Sumera ZaibDepartment of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab, Lahore, 54590, Pakistan.
Humaira HussianDepartment of Biochemistry, Abbottabad University of Science and Technology (AUST), Abbottabad, 22500, Khyber Pakhtunkhwa, Pakistan.
Magda H AbdellattifDepartment of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.
Afnan JanDepartment of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Aliya IbrarDepartment of Chemistry, Faculty of Physical and Applied Sciences, The University of Haripur, Haripur, KPK, 22620, Pakistan.
Ajmal KhanNatural and Medical Sciences Research Center, University of Nizwa, , Birkat Al Mauz, Nizwa, PO Box 33, 616, Oman.
Ahmed Al-HarrasiNatural and Medical Sciences Research Center, University of Nizwa, , Birkat Al Mauz, Nizwa, PO Box 33, 616, Oman.

Funding

Taif University, Saudi Arabia TU-DSPP-2024-19
6 · The paper itself

Abstract

introductionTyrosinase, a copper-containing enzyme, is responsible for melanin production, and its overactivity can lead to hyperpigmentation.

methodsThis study aimed to evaluate triazolothiadiazoles (3a-h, 4a-f) and triazolothiadiazines (5a-h) against human and mushroom tyrosinase isozymes.

resultsSeveral derivatives, such as 3a-3b, 3d, 4c-4f, 5d, and 5e, were identified as potent and selective inhibitors of mushroom tyrosinase, with IC

conclusionAdditionally, the pharmacokinetic profile of these compounds highlighted promising drug-like properties, making them potential candidates for the development of effective therapeutics for skin disorders.

Indexed as

Drug DiscoveryEnzyme InhibitorsMonophenol MonooxygenaseSkin DiseasesThiadiazinesThiadiazolesAgaricalesHumansKineticsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipEnzyme InhibitorsMonophenol MonooxygenaseThiadiazinesThiadiazolescytotoxicity.enzyme kineticsfused heterocyclesmelanin synthesismolecular dockingTyrosinase inhibitors

Identifiers

PMID40776643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.